Apontis Pharma: Solid Results Following A Successful IPO
Edison Group | Aug 24, 2021 12:43
Following its successful IPO in May, Apontis Pharma's (DE:APPHG) maiden results highlight that the expansion of its single pill franchise continues at pace and should continue to provide high double-digit sales growth. These pills are combinations of commonly co-prescribed generic drugs that have been reformulated into one branded pill. We believe an increasing mix of these higher-margin single pills will improve profitability. Apontis’s shares have appreciated since they were initially priced at €19.0/share (up c 16%) and the company has a market cap of €187m with an EV of c €157m.h3 Share Price Graph/h3
Apontis Pharma is focused purely on the German market, where it has a rich commercial heritage (formerly Schwarz Pharma and then UCB Innere Medizin). Its current focus is on driving uptake of its single pills for cardiovascular disease, but it also co-markets branded respiratory and diabetes drugs for large-cap pharma companies.
h3 Bull/h3- Growing recognition of the compliance, patient outcome and cost benefits of its single pills presents a strong tailwind.
- Cardiovascular disease remains on the rise in Germany and is the leading cause of death.
- Co-marketing agreements with AstraZeneca (NASDAQ:AZN) and Novartis offers synergies for its reps.
- Failure to execute on co-marketing agreements could lead to early termination; failure to replace or renew these would impact growth ambitions.
- Public tenders in Germany could place pricing pressure on its drugs and squeeze margins.
- Capitalised R&D inflates intangibles; pipeline attrition may lead to write-downs or impairments.
During H121, revenues grew by 36% to €24.0m, primarily driven by single pill sales which grew 83% to €14.0m. Apontis continues to benefit from prescriber and payor adoption of its single pills, with AXA Health Insurance recommending its antihypertensives to policy holders during the period. Single pills represented 58% of the revenue mix and margins are improving as a result, with the adjusted EBITDA margin up at 11.8% (H120: -8.1%). Substantial investment in its single pill portfolio can be expected over the mid-term to sustain growth momentum, and c €20m of the IPO proceeds are ear-marked for this purpose. Following the IPO, the company is now debt-free with cash of €30.5m at 30 June.
h3 Promising mid-term outlook/h3
Get The App
Management has guided that based on its existing and developmental portfolio, single pill sales could grow by c €100m from a base of €19.0m in 2020. Assuming these are fully realised by end-2030 would imply a c 20% sales CAGR. An increasing mix of these higher-margin products (>70% gross) should enable it to hit its mid-term group EBITDA target of 30%. Despite being lower margin, co-marketing agreements with AstraZeneca and Novartis for several respiratory and diabetes drugs clearly offer synergies to its single pills and ultimately provide an entry point for its c 130 sales reps, who market to c 23k physicians in Germany.
h3 Valuation: High growth and an enticing margin story/h3Based on revenue expectations for FY21 (consensus: €49.3m; management: €48.5m) Apontis currently trades at c 3.2x EV/sales, a slight discount to the peer average of c 3.6x. Based on FY21 adjusted EBITDA it trades at c 39x (consensus: €4.0m) or c 28x EV/EBITDA (management: €5.5m), a premium to the peer average of c 14x. Recognition of its double-digit sales growth potential, coupled with the potential for a strong margin story, should continue to underpin share momentum.
h3 Consensus Estimates/h3
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.